Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.

UNLABELLED A33, a monoclonal antibody that targets colon carcinomas, was labeled with (125)I or (131)I and the relative therapeutic efficacy of the 2 radiolabeled species was compared in a human colon cancer xenograft system. METHODS Nude mice bearing human SW1222 colon carcinoma xenografts were administered escalating activities of (125)I-A33 (9.25-148 MBq) or (131)I-A33 (0.925-18.5 MBq), (125)I- and (131)I-labeled control antibodies, unlabeled antibody, or no antibody. The effects of treatment were assessed using the endpoints of tumor growth delay and cure. RESULTS Tumor growth delay increased with administered activity for all radiolabeled antibodies. Approximately 4.5 times more activity was required for (125)I-A33 to produce therapeutic effects that were equivalent to those of (131)I-A33. This ratio was approximately 7 for a nonspecific, noninternalizing isotype-matched, radiolabeled control antibody. Unlabeled A33 antibody had no effect on tumor growth. Approximately 10 times more activity of (125)I-A33 produced toxicity similar to that of (131)I-A33, and this ratio fell to approximately 6 for radiolabeled control antibody. CONCLUSION Treatment with (125)I-A33 resulted in a relative therapeutic gain of approximately 2 compared with (131)I-A33 in this experimental system.

[1]  A. Scott,et al.  Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Scott,et al.  Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R K Jain,et al.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.

[4]  K. Sastry,et al.  Biological effects of the Auger emitter iodine-125: a review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6. , 1992, Medical physics.

[5]  L. Old,et al.  Pharmacokinetics and microdistribution of polyethylene glycol‐modified humanized A33 antibody targeting colon cancer xenografts , 2000, International journal of cancer.

[6]  M. Stabin Dosimetry of External Beta Rays for Radiation Protection , 1998 .

[7]  L. Old,et al.  Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. , 1987, Clinical immunology and immunopathology.

[8]  Hofer Kg Radiation biology and potential therapeutic applications of radionuclides. , 1980 .

[9]  A. Scott,et al.  Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. , 1998, International journal of oncology.

[10]  J. Humm,et al.  131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  K. Hofer Radiation biology and potential therapeutic applications of radionuclides. , 1980, Bulletin du cancer.

[12]  J. Humm,et al.  Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. , 1994, Medical physics.

[13]  F. Real,et al.  Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Schrappe,et al.  Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. , 1992, Cancer research.

[15]  D. Goldenberg,et al.  Therapeutic efficacy and dose‐limiting toxicity of auger‐electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I‐ vs. 131I‐labeled CO17‐1A in a human colorectal cancer model , 1998, International journal of cancer.

[16]  Z. Steplewski,et al.  Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells. , 1989, Cancer research.

[17]  J. Humm,et al.  Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.